New High - Stock Screener

Market Cap	945.97M	EPS (ttm)	0.44
P/E	33.41	EPS this Y	-29.54%
Forward P/E	18.00	EPS next Y	-50.90%
PEG	1.73	EPS past 5Y	15.22%
P/S	3.11	EPS next 5Y	19.34%
P/B	1.51	EPS Q/Q	-64.89%
Dividend	-	Sales Q/Q	0.00%
Insider Own	1.09%	Inst Own	108.71%
Insider Trans	0.58%	Inst Trans	-2.65%
Short Float	15.16%	Earnings	Nov 01/a
Analyst Recom	3.00	Target Price	15.00
Avg Volume	717.65K	52W Range	10.64 - 14.77

Nov-18-23 07:03AM	Insider Sell Alert: Marianne Zhen Offloads Shares of Innoviva Inc (GuruFocus.com)
Nov-03-23 06:00AM	Innoviva Inc (INVA) Reports Q3 2023 Financial Results: Net Income Drops to $82.0 Million (GuruFocus.com)
Nov-01-23 05:32PM	Innoviva: Q3 Earnings Snapshot (Associated Press Finance)
04:15PM	Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress (Business Wire)
04:05PM	Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea (Business Wire)
Sep-19-23 08:30AM	Innoviva to Participate in the Cantor Global Healthcare Conference (Business Wire)
Sep-18-23 08:00AM	XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults (Business Wire)
Aug-25-23 04:52PM	Innoviva Appoints Stephen Basso as Chief Financial Officer (Business Wire)
Aug-02-23 05:18PM	Innoviva: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress (Business Wire)

Innoviva, Inc. is engaged in the development, commercialization, and financial management of biopharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate, and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Zhen Marianne	Chief Accounting Officer	Nov 15	Sale	13.99	10,994	153,810	40,158	Nov 17 04:30 PM
DENNER ALEXANDER J	10% Owner	Jun 06	Buy	13.05	8,000	104,384	7,215,000	Jun 07 08:10 PM
DENNER ALEXANDER J	10% Owner	Jun 05	Buy	13.04	7,000	91,297	7,207,000	Jun 07 08:10 PM
DENNER ALEXANDER J	10% Owner	May 30	Buy	13.01	120,000	1,560,648	7,200,000	May 30 07:01 PM
DENNER ALEXANDER J	10% Owner	May 26	Buy	13.12	30,000	393,729	7,080,000	May 30 07:01 PM

1⋯7 8 9 10 11 12

Upgrade your FINVIZ experience